Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Renovorx Inc
(NQ:
RNXT
)
1.270
+0.010 (+0.79%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renovorx Inc
< Previous
1
2
3
Next >
Catalyst Watch: RenovoRx, Inc. Stock Jumps 14% Ahead of Thursday’s Phase III TIGeR-PaC Trial Update ($RNXT)
June 28, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Catalyst Watch: RenovoRx, Inc. Nears June 29th Data Release From Its Phase III TIGeR-PaC Trial Targeting Pancreatic Cancer ($RNXT)
June 26, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
June 20, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
June 12, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
June 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
May 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the LD Micro Invitational XIII Conference
May 24, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
May 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
April 28, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
April 27, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
April 14, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
April 11, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
March 30, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
March 08, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fueled Breakout ($RNXT)
March 06, 2023
Via
AB Newswire
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
March 02, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Shares Surge 117% YTD As Multiple Catalysts Come Into Focus ($RNXT)
March 02, 2023
Via
AB Newswire
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
March 01, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx, Inc. Shares Rally As RenovoTAMP Cancer Treatment Platform Continues To Attract Sector Attention ($RNXT)
March 01, 2023
Via
AB Newswire
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
January 25, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
January 18, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
January 05, 2023
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
December 15, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
November 17, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Third Quarter 2022 Financial Results
November 14, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
October 21, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
October 04, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
September 28, 2022
From
RenovoRx, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.